AAV vectorization of DSB-mediated gene editing technologies

Current Gene Therapy

Volumn 16, Issue 3, 2016, Pages 207-219

  Moser, Rachel J ^a   Hirsch, Matthew L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

AAV Vectorization; CRISPR Cas9; DNA; DSB; ZFNs

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHIMERIC ANTIGEN RECEPTOR; MESSENGER RNA; PARVOVIRUS VECTOR; REACTIVE OXYGEN METABOLITE; RESTRICTION ENDONUCLEASE; ZINC FINGER NUCLEASE; DEOXYRIBONUCLEASE; ZINC FINGER PROTEIN;

ADENO ASSOCIATED VIRUS; DNA MODIFICATION; DOUBLE STRANDED DNA BREAK; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; GENETIC ENGINEERING; GENETIC MANIPULATION; GENETIC TRANSDUCTION; GOOD MANUFACTURING PRACTICE; HUMAN; INDEL MUTATION; NONHUMAN; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS GENOME; ANIMAL; CRISPR CAS SYSTEM; DEPENDOPARVOVIRUS; GENE EDITING; GENE THERAPY; GENE VECTOR; GENETICS; PROCEDURES;

ANIMALS; CRISPR-CAS SYSTEMS; DEOXYRIBONUCLEASES; DEPENDOVIRUS; DNA BREAKS, DOUBLE-STRANDED; GENE EDITING; GENE TARGETING; GENETIC THERAPY; GENETIC VECTORS; HUMANS; ZINC FINGERS;

EID: 84978196200     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523216666160602213738     Document Type: Review

References (150)

1. Capecchi MR. Altering the genome by homologous recombination. Science 1989; 244(4910): 1288-92.
2. Capecchi MR. Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century. Nat Rev Genet 2005; 6(6): 507-12.
3. Gaj T, Gersbach CA, Barbas CF III. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 2013; 31(7): 397-405.
4. Hendrie PC, Russell DW. Gene targeting with viral vectors. Mol Ther 2005 Jul; 12(1): 9-17.
5. Hirata RK, Russell DW. Design and packaging of adeno-associated virus gene targeting vectors. J Virol 2000; 74(10): 4612-20.
6. LaFountaine JS, Fathe K, Smyth HD. Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9. Int J Pharm 2015; 494(1): 180-94.
7. Hirsch ML, Samulski RJ. AAV-mediated gene editing via doublestrand break repair. Methods Mol Biol 2014; 1114: 291-307.
8. Porteus MH, Carroll D. Gene targeting using zinc finger nucleases. Nat Biotechnol 2005; 23(8): 967-73.
9. Porteus MH, Cathomen T, Weitzman MD, Baltimore D. Efficient gene targeting mediated by adeno-associated virus and DNA double-strand breaks. Mol Cell Biol 2003; 23(10): 3558-65.
10. Stuckey S, Storici F. Genetic modification stimulated by the induction of a site-specific break distant from the locus of correction in haploid and diploid yeast Saccharomyces cerevisiae. Methods Mol Biol 2014; 1114: 309-24.
11. Szostak JW, Orr-Weaver TL, Rothstein RJ, Stahl FW. The doublestrand-break repair model for recombination. Cell 1983; 33(1): 25-35.
12. Sedivy JM, Sharp PA. Positive genetic selection for gene disruption in mammalian cells by homologous recombination. Proc Natl Acad Sci USA 1989; 86(1): 227-31.
13. Kakarougkas A, Jeggo PA. DNA DSB repair pathway choice: an orchestrated handover mechanism. Br J Radiol 2014; 87(1035): 20130685.
14. Takata M, Sasaki MS, Sonoda E, et al. Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromo somal integrity in vertebrate cells. EMBO J 1998; 17(18): 5497-508.
15. Porteus MH, Baltimore D. Chimeric nucleases stimulate gene targeting in human cells. Science 2003; 300(5620): 763.
16. Cai M, Yang Y. Targeted genome editing tools for disease modeling and gene therapy. Curr Gene Ther 2014; 14(1): 2-9.
17. Hastie E, Samulski RJ. Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success-a personal perspective. Hum Gene Ther 2015; 26(5): 257-65.
18. Barker SE, Broderick CA, Robbie SJ, et al. Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice. J Gene Med 2009; 11(6): 486-97.
19. Gaudet D, Méthot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipidol 2012; 23(4): 310-20.
20. Monahan PE. Gene therapy in an era of emerging treatment options for hemophilia B. J Thromb Haemost 2015; 13(Suppl. 1): S151-60.
21. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011; 12(5): 341-55.
22. Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science 1965; 149(3685): 754-6.
23. Carter BJ, Khoury G, Denhardt DT. Physical map and strand polarity of specific fragments of adenovirus-associated virus DNA produced by endonuclease R-EcoRI. J Virol 1975; 16(3): 559-68.
24. Rose JA, Berns KI, Hoggan MD, Koczot FJ. Evidence for a singlestranded adenovirus-associated virus genome: formation of a DNA density hybrid on release of viral DNA. Proc Natl Acad Sci USA 1969; 64(3): 863-9.
25. Balakrishnan B, Jayandharan GR. Basic biology of adenoassociated virus (AAV) vectors used in gene therapy. Curr Gene Ther 2014; 14(2): 86-100.
26. Pereira DJ, McCarty DM, Muzyczka N. The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection. J Virol 1997; 71(2): 1079-88.
27. King JA, Dubielzig R, Grimm D, Kleinschmidt JA. DNA helicasemediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J 2001; 20(12): 3282-91.
28. Kyöstiö SR, Owens RA, Weitzman MD, Antoni BA, Chejanovsky N, Carter BJ. Analysis of adeno-associated virus (AAV) wild-type and mutant Rep proteins for their abilities to negatively regulate AAV p5 and p19 mRNA levels. J Virol 1994; 68(5): 2947-57.
29. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008; 21(4): 583-93.
30. Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci USA 2010; 107(22): 10220-5.
31. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 2001; 75(15): 6884-93.
32. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72(2): 1438-45.
33. Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol 2000; 74(6): 2777-85.
34. Douar AM, Poulard K, Stockholm D, Danos O. Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J Virol 2001; 75(4): 1824-33.
35. Sonntag F, Bleker S, Leuchs B, Fischer R, Kleinschmidt JA. Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J Virol 2006; 80(22): 11040-54.
36. Johnson JS, Samulski RJ. Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J Virol 2009; 83(6): 2632-44.
37. Nicolson SC, Samulski RJ. Recombinant adeno-associated virus utilizes host cell nuclear import machinery to enter the nucleus. J Virol 2014; 88(8): 4132-44.
38. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70(5): 3227-34.
39. Nakai H, Storm TA, Kay MA. Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J Virol 2000; 74(20): 9451-63.
40. Zhou X, Zeng X, Fan Z, Li C, McCown T, Samulski RJ, et al. Adeno-associated virus of a single-polarity DNA genome is capable of transduction in vivo. Mol Ther 2008 Mar; 16(3): 494-9.
41. Choi VW, Samulski RJ, McCarty DM. Effects of adeno-associated virus DNA hairpin structure on recombination. J Virol 2005; 79(11): 6801-7.
42. Inagaki K, Ma C, Storm TA, Kay MA, Nakai H. The role of DNAPKcs and artemis in opening viral DNA hairpin termini in various tissues in mice. J Virol 2007; 81(20): 11304-21.
43. Choi VW, McCarty DM, Samulski RJ. Host cell DNA repair pathways in adeno-associated viral genome processing. J Virol 2006; 80(21): 10346-56.
44. Duan D, Sharma P, Yang J, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 1998; 72(11): 8568-77.
45. Duan D, Yan Z, Yue Y, Engelhardt JF. Structural analysis of adeno-associated virus transduction circular intermediates. Virology 1999; 261(1): 8-14.
46. Yang J, Zhou W, Zhang Y, Zidon T, Ritchie T, Engelhardt JF. Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J Virol 1999; 73(11): 9468-77.
47. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70(11): 8098-108.
48. Penaud-Budloo M, Le Guiner C, Nowrouzi A, et al. Adenoassociated virus vector genomes persist as episomal chromatin in primate muscle. J Virol 2008; 82(16): 7875-85.
49. Kotin RM, Siniscalco M, Samulski RJ, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990; 87(6): 2211-5.
50. Samulski RJ, Zhu X, Xiao X, et al. Targeted integration of adenoassociated virus (AAV) into human chromosome 19. EMBO J 1991; 10(12): 3941-50.
51. Janovitz T, Klein IA, Oliveira T, et al. High-throughput sequencing reveals principles of adeno-associated virus serotype 2 integration. J Virol 2013; 87(15): 8559-68.
52. Hüser D, Gogol-Döring A, Chen W, Heilbronn R. Adenoassociated virus type 2 wild-type and vector-mediated genomic integration profiles of human diploid fibroblasts analyzed by thirdgeneration PacBio DNA sequencing. J Virol 2014; 88(19): 11253-63.
53. Urcelay E, Ward P, Wiener SM, Safer B, Kotin RM. Asymmetric replication in vitro from a human sequence element is dependent on adeno-associated virus Rep protein. J Virol 1995; 69(4): 2038-46.
54. Dyall J, Berns KI. Site-specific integration of adeno-associated virus into an episome with the target locus via a deletionsubstitution mechanism. J Virol 1998; 72(7): 6195-8.
55. Li C, Hirsch M, Carter P, et al. A small regulatory element from chromosome 19 enhances liver-specific gene expression. Gene Ther 2009; 16(1): 43-51.
56. Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science 2013; 339(6121): 823-6.
57. Wang J, Exline CM, DeClercq JJ, et al. Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat Biotechnol 2015; 33(12): 1256-63.
58. Xiao X, Xiao W, Li J, Samulski RJ. A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J Virol 1997; 71(2): 941-8.
59. Samulski RJ, Berns KI, Tan M, Muzyczka N. Cloning of adenoassociated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA 1982; 79(6): 2077-81.
60. Srivastava CH, Samulski RJ, Lu L, Larsen SH, Srivastava A. Construction of a recombinant human parvovirus B19: adenoassociated virus 2 (AAV) DNA inverted terminal repeats are functional in an AAV-B19 hybrid virus. Proc Natl Acad Sci USA 1989; 86(20): 8078-82.
61. Samulski RJ, Srivastava A, Berns KI, Muzyczka N. Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV. Cell 1983; 33(1): 135-43.
62. Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther 2012 Apr; 20(4): 699-708.
63. Liu Y, Siriwon N, Rohrs JA, Wang P. Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy. Curr Pharm Des 2015; 21(22): 3248-56.
64. Büning H, Huber A, Zhang L, Meumann N, Hacker U. Engineering the AAV capsid to optimize vector-host-interactions. Curr Opin Pharmacol 2015; 24: 94-104.
65. Cai X, Conley SM, Naash MI. RPE65: role in the visual cycle, human retinal disease, and gene therapy. Ophthalmic Genet 2009; 30(2): 57-62.
66. McClements ME, MacLaren RE. Gene therapy for retinal disease. Transl Res 2013; 161(4): 241-54.
67. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358(21): 2240-8.
68. Schuster BS, Kim AJ, Kays JC, Kanzawa MM, Guggino WB, Boyle MP, et al. Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors. Mol Ther 2014 Aug; 22(8): 1484-93.
69. Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371(21): 1994-2004.
70. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirusassociated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365(25): 2357-65.
71. Jackson KL, Dayton RD, Klein RL. AAV9 supports wide-scale transduction of the CNS and TDP-43 disease modeling in adult rats. Mol Ther Methods Clin Dev 2015; 2: 15036.
72. Wasala NB, Shin JH, Duan D. The evolution of heart gene delivery vectors. J Gene Med 2011; 13(10): 557-65.
73. Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS, et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 2012 Feb; 20(2): 443-55.
74. Lin SW, Hensley SE, Tatsis N, Lasaro MO, Ertl HC. Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J Clin Invest 2007; 117(12): 3958-70.
75. Leone P, Shera D, McPhee SW, et al. Long-term follow-up after gene therapy for canavan disease. Sci Transl Med 2012; 4(165): 165ra163.
76. Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 2010; 363(15): 1429-37.
77. Hirsch ML. Adeno-associated virus inverted terminal repeats stimulate gene editing. Gene Ther 2015; 22(2): 190-5.
78. Hirsch ML, Storici F, Li C, Choi VW, Samulski RJ. AAV recombineering with single strand oligonucleotides. PLoS One 2009; 4(11): e7705.
79. Thomas KR, Folger KR, Capecchi MR. High frequency targeting of genes to specific sites in the mammalian genome. Cell 1986; 44(3): 419-28.
80. Russell DW, Hirata RK. Human gene targeting by viral vectors. Nat Genet 1998; 18(4): 325-30.
81. Smithies O, Gregg RG, Boggs SS, Koralewski MA, Kucherlapati RS. Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature 1985; 317(6034): 230-4.
82. Hirsch ML, Green L, Porteus MH, Samulski RJ. Selfcomplementary AAV mediates gene targeting and enhances endonuclease delivery for double-strand break repair. Gene Ther 2010; 17(9): 1175-80.
83. Earley LF, Kawano Y, Adachi K, Sun XX, Dai MS, Nakai H. Identification and characterization of nuclear and nucleolar localization signals in the adeno-associated virus serotype 2 assemblyactivating protein. J Virol 2015; 89(6): 3038-48.
84. Kohli M, Rago C, Lengauer C, Kinzler KW, Vogelstein B. Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses. Nucleic Acids Res 2004; 32(1): e3.
85. Russell DW, Hirata RK. Human gene targeting favors insertions over deletions. Hum Gene Ther 2008; 19(9): 907-14.
86. Paulk NK, Loza LM, Finegold MJ, Grompe M. AAV-mediated gene targeting is significantly enhanced by transient inhibition of nonhomologous end joining or the proteasome in vivo. Hum Gene Ther 2012; 23(6): 658-65.
87. Trobridge G, Hirata RK, Russell DW. Gene targeting by adenoassociated virus vectors is cell-cycle dependent. Hum Gene Ther 2005; 16(4): 522-6.
88. Asuri P, Bartel MA, Vazin T, Jang JH, Wong TB, Schaffer DV. Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells. Mol Ther 2012 Feb; 20(2): 329-8.
89. Khan IF, Hirata RK, Wang PR, Li Y, Kho J, Nelson A, et al. Engineering of human pluripotent stem cells by AAV-mediated gene targeting. Mol Ther 2010; 18(6): 1192-9.
90. Hirsch ML, Fagan BM, Dumitru R, et al. Viral single-strand DNA induces p53-dependent apoptosis in human embryonic stem cells. PLoS One 2011; 6(11): e27520.
91. Brown NJ, Hirsch ML. Adeno-associated virus (AAV) gene delivery in stem cell therapy. Discov Med 2015; 20(111): 333-42.
92. Rapti K, Stillitano F, Karakikes I, et al. Effectiveness of gene delivery systems for pluripotent and differentiated cells. Mol Ther Methods Clin Dev 2015; 2: 14067.
93. Riolobos L, Hirata RK, Turtle CJ, Wang PR, Gornalusse GG, Zavajlevski M, et al. HLA engineering of human pluripotent stem cells. Mol Ther 2013; 21(6): 1232-41.
94. Ellis BL, Hirsch ML, Porter SN, Samulski RJ, Porteus MH. Zincfinger nuclease-mediated gene correction using single AAV vector transduction and enhancement by Food and Drug Administrationapproved drugs. Gene Ther 2013; 20(1): 35-42.
95. Choulika A, Perrin A, Dujon B, Nicolas JF. Induction of homologous recombination in mammalian chromosomes by using the ISceI system of Saccharomyces cerevisiae. Mol Cell Biol 1995; 15(4): 1968-73.
96. Donoho G, Jasin M, Berg P. Analysis of gene targeting and intrachromosomal homologous recombination stimulated by genomic double-strand breaks in mouse embryonic stem cells. Mol Cell Biol 1998; 18(7): 4070-8.
97. Taghian DG, Nickoloff JA. Chromosomal double-strand breaks induce gene conversion at high frequency in mammalian cells. Mol Cell Biol 1997; 17(11): 6386-93.
98. Händel EM, Gellhaus K, Khan K, et al. Versatile and efficient genome editing in human cells by combining zinc-finger nucleases with adeno-associated viral vectors. Hum Gene Ther 2012; 23(3): 321-9.
99. Gellhaus K, Cornu TI, Heilbronn R, Cathomen T. Fate of recombinant adeno-associated viral vector genomes during DNA doublestrand break-induced gene targeting in human cells. Hum Gene Ther 2010; 21(5): 543-53.
100. Hirsch ML, Agbandje-McKenna M, Samulski RJ. Little vector, big gene transduction: fragmented genome reassembly of adenoassociated virus. Mol Ther 2010; 18(1): 6-8.
101. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014; 370(10): 901-10.
102. Smith J, Bibikova M, Whitby FG, Reddy AR, Chandrasegaran S, Carroll D. Requirements for double-strand cleavage by chimeric restriction enzymes with zinc finger DNA-recognition domains. Nucleic Acids Res 2000; 28(17): 3361-9.
103. Händel EM, Cathomen T. Zinc-finger nuclease based genome surgery: it's all about specificity. Curr Gene Ther 2011; 11(1): 28-37.
104. Wang R, Preamplume G, Terns MP, Terns RM, Li H. Interaction of the Cas6 riboendonuclease with CRISPR RNAs: recognition and cleavage. Structure 2011; 19(2): 257-64.
105. Anguela XM, Sharma R, Doyon Y, et al. Robust ZFN-mediated genome editing in adult hemophilic mice. Blood 2013; 122(19): 3283-7.
106. Sharma R, Anguela XM, Doyon Y, et al. In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood 2015; 126(15): 1777-84.
107. Landau DJ, Brooks ED, Perez-Pinera P, et al. In vivo zinc finger nuclease-mediated targeted integration of a glucose-6-phosphatase transgene promotes survival in mice with glycogen storage disease type IA. Mol Ther 2016; 24(4): 697-706.
108. Ghosh A, Allamarvdasht M, Pan CJ, et al. Long-term correction of murine glycogen storage disease type Ia by recombinant adenoassociated virus-1-mediated gene transfer. Gene Ther 2006; 13(4): 321-9.
109. Koeberl DD, Pinto C, Sun B, Li S, Kozink DM, Benjamin DK Jr, et al. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. Mol Ther 2008; 16(4): 665-72.
110. Luo X, Hall G, Li S, Bird A, Lavin PJ, Winn MP, et al. Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector. Mol Ther 2011; 19(11): 1961-70.
111. Lambert JP, Brunt PW, Mowat NA, et al. The value of prescribed 'high-fibre' diets for the treatment of the irritable bowel syndrome. Eur J Clin Nutr 1991; 45(12): 601-9.
112. Weinstein DA, Correia CE, Conlon T, et al. Adeno-associated virus-mediated correction of a canine model of glycogen storage disease type Ia. Hum Gene Ther 2010; 21(7): 903-10.
113. Sternberg SH, Redding S, Jinek M, Greene EC, Doudna JA. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 2014; 507(7490): 62-7.
114. Schmidt F, Grimm D. CRISPR genome engineering and viral gene delivery: a case of mutual attraction. Biotechnol J 2015; 10(2): 258-72.
115. Gonzalez F. CRISPR/Cas9 genome editing in human pluripotent stem cells. Harnessing human genetics in a dish. Deve Dyn 2016; 4: doi: 10. 1002/dvdy. 24414.
116. An L, Hu Y, Chang S, et al. Efficient generation of FVII gene knockout mice using CRISPR/Cas9 nuclease and truncated guided RNAs. Sci Rep 2016; 6: 25199.
117. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014; 157(6): 1262-78.
118. Kaczmarczyk L, Mende Y, Zevnik B, Jackson WS. Manipulating the prion protein gene sequence and expression levels with CRISPR/Cas9. PLoS One 2016; 11(4): e0154604.
119. Wallace J, Hu R, Mosbruger TL, et al. Genome-wide CRISPRCas9 screen identifies MicroRNAs that regulate myeloid leukemia cell growth. PLoS One 2016; 11(4): e0153689.
120. Feng W, Li HC, Xu K, et al. SHCBP1 is over-expressed in breast cancer and is important in the proliferation and apoptosis of the human malignant breast cancer cell line. Gene 2016; 587(1): 91-7.
121. Platt RJ, Chen S, Zhou Y, et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 2014; 159(2): 440-55.
122. Lee CM, Cradick TJ, Fine EJ, Bao G. Nuclease target site selection for maximizing on-target activity and minimizing off-target effects in genome editing. Mol Ther 2016 Jan; 11.
123. Fine EJ, Appleton CM, White DE, et al. Trans-spliced Cas9 allows cleavage of HBB and CCR5 genes in human cells using compact expression cassettes. Sci Rep 2015; 5: 10777.
124. Truong DJ, Kühner K, Kühn R, et al. Development of an inteinmediated split-Cas9 system for gene therapy. Nucleic Acids Res 2015; 43(13): 6450-8.
125. Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun 2015; 6: 6244.
126. Swiech L, Heidenreich M, Banerjee A, et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol 2015; 33(1): 102-6.
127. Mefferd AL, Kornepati AV, Bogerd HP, Kennedy EM, Cullen BR. Expression of CRISPR/Cas single guide RNAs using small tRNA promoters. RNA 2015; 21(9): 1683-9.
128. Ran FA, Cong L, Yan WX, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 2015; 520(7546): 186-91.
129. Kennedy EM, Cullen BR. Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment. Virology 2015; 479-480: 213-20.
130. Friedland AE, Baral R, Singhal P, et al. Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adenoassociated virus delivery and paired nickase applications. Genome Biol 2015; 16: 257.
131. Tabebordbar M, Zhu K, Cheng JK, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 2016; 351(6271): 407-11.
132. Long C, Amoasii L, Mireault AA, et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 2016; 351(6271): 400-3.
133. Yang Y, Wang L, Bell P, et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol 2016; 34(3): 334-8.
134. Fu Y, Foden JA, Khayter C, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 2013; 31(9): 822-6.
135. Hsu PD, Scott DA, Weinstein JA, et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 2013; 31(9): 827-32.
136. Wang D, Mou H, Li S, et al. Adenovirus-mediated somatic genome editing of Pten by CRISPR/Cas9 in mouse liver in spite of Cas9-specific immune responses. Hum Gene Ther 2015; 26(7): 432-42.
137. Aubert M, Boyle NM, Stone D, et al. In vitro inactivation of latent HSV by targeted mutagenesis using an HSV-specific homing endonuclease. Mol Ther Nucleic Acids 2014; 3: e146.
138. Gupta RM, Musunuru K. Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. J Clin Invest 2014; 124(10): 4154-61.
139. Beurdeley M, Bietz F, Li J, et al. Compact designer TALENs for efficient genome engineering. Nat Commun 2013; 4: 1762.
140. Pruett-Miller SM, Reading DW, Porter SN, Porteus MH. Attenuation of zinc finger nuclease toxicity by small-molecule regulation of protein levels. PLoS Genet 2009; 5(2): e1000376.
141. Konermann S, Brigham MD, Trevino AE, et al. Optical control of mammalian endogenous transcription and epigenetic states. Nature 2013; 500(7463): 472-6.
142. Hemphill J, Borchardt EK, Brown K, Asokan A, Deiters A. Optical control of CRISPR/Cas9 gene editing. J Am Chem Soc 2015; 137(17): 5642-5.
143. Mock U, Machowicz R, Hauber I, et al. mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5. Nucleic Acids Res 2015; 43(11): 5560-71.
144. Gaj T, Guo J, Kato Y, Sirk SJ, Barbas CF III. Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat Methods 2012; 9(8): 805-7.
145. Yu X, Liang X, Xie H, et al. Improved delivery of Cas9 protein/gRNA complexes using lipofectamine CRISPRMAX. Biotechnol Lett 2016; 38(6): 919-29.
146. Ramakrishna S, Kwaku Dad AB, Beloor J, Gopalappa R, Lee SK, Kim H. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res 2014; 24(6): 1020-7.
147. Sather BD, Romano Ibarra GS, Sommer K, et al. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med 2015; 7(307): 307ra156.
148. Boissel S, Jarjour J, Astrakhan A, et al. megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering. Nucleic Acids Res 2014; 42(4): 2591-601.
149. De Ravin SS, Reik A, Liu PQ, et al. Targeted gene addition in human CD34(+) hematopoietic cells for correction of X-linked chronic granulomatous disease. Nat Biotechnol 2016; 34(4): 424-9.
150. Dreyer AK, Hoffmann D, Lachmann N, et al. TALEN-mediated functional correction of X-linked chronic granulomatous disease in patient-derived induced pluripotent stem cells. Biomaterials 2015; 69: 191-200.